AI could catch returning cancer months earlier than current tests

NCT ID NCT07189520

Not yet recruiting Diagnosis Sponsor: Università Politecnica delle Marche Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will test whether an artificial intelligence system can detect minimal residual disease—tiny amounts of cancer left after surgery—and predict recurrence in 700 people with rectal cancer. The AI combines blood tests, genetic data, and scans to create a more complete picture than standard methods. If it works, it could lead to earlier, more personalized treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Artificial intelligence (AI) software
What this could lead to: If successful, this AI could help doctors detect leftover cancer cells and predict return of rectal cancer much earlier than standard tests, potentially guiding more timely treatment.
What could go wrong: This is an early-stage study that hasn't started recruiting yet. The AI may not perform better than existing methods in real-world settings, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.